Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-436 | Ipatasertib | AKT | PI3K/mTOR | 25.8679 | 0.6111 | 0.1038 | 0.0116 | 0.4073 | 383.9431 | 0.92516 |
MDA-MB-361 | Olaparib | PARP | Misc | 4.8624 | 0.0945 | 0.1038 | 0.0095 | 1.2844 | 11.0203 | 0.97233 |
MDA-MB-157 | Alpelisib | PI3Ka | PI3K/mTOR | 9.7515 | 0.4924 | 0.1041 | 0.0114 | 0.6775 | 11.4208 | 0.96993 |
HCC1428 | Neratinib | EGFR/HER2 | RTK | 1.4327 | -0.0412 | 0.1042 | 0.0283 | 1.5482 | 2.7752 | 0.9933 |
MDA-MB-231 | Neratinib | EGFR/HER2 | RTK | 1.4329 | -0.0957 | 0.1056 | 0.0516 | 1.6284 | 2.8124 | 0.99527 |
HCC1937 | Abemaciclib | CDK4/6 | Cell cycle | 4.8534 | 0.3020 | 0.1062 | 0.0050 | 0.9638 | 6.1622 | 0.98334 |
MCF7 | Cabozantinib | VEGFR2/MET | RTK | 4.8819 | -0.0993 | 0.1069 | 0.0302 | 1.8080 | 8.9638 | 0.99698 |
HCC1419 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.5051 | 0.1071 | 0.0007 | 1.4251 | 0.82031 | 0.95841 |
HCC1806 | Trametinib | MEK | MAPK/nRTK | Inf | 0.7036 | 0.1086 | 0.0280 | 4.8006 | 0.007609 | 0.89189 |
CAMA-1 | Cediranib | VEGFR/cKIT | RTK | 5.0236 | -0.2923 | 0.1089 | 0.0448 | 2.4671 | 7.8416 | 0.99299 |
SUM1315MO2 | Cabozantinib | VEGFR2/MET | RTK | 4.5316 | 0.1095 | 0.1089 | 0.0163 | 1.1058 | 12.2361 | 0.99069 |
HCC1419 | PF-4708671 | p70S6K | PI3K/mTOR | 5.2795 | 0.3488 | 0.1117 | -0.0019 | 1.0898 | 4.6502 | 0.97858 |
HME1 | Alpelisib | PI3Ka | PI3K/mTOR | 6.0356 | 0.3071 | 0.1123 | 0.0079 | 0.9018 | 20.4027 | 0.98253 |
MCF 10A | Alpelisib | PI3Ka | PI3K/mTOR | 17.193 | 0.5787 | 0.1126 | -0.0029 | 0.4411 | 201.6709 | 0.99492 |
MCF 10A | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.7889 | 0.1130 | 0.0000 | 0.4668 | 0.070049 | 0.96385 |
HCC1395 | Vorinostat | HDAC | Misc | 3.2812 | -0.0589 | 0.1137 | 0.0365 | 2.1496 | 3.8175 | 0.99171 |
SUM159PT | Ipatasertib | AKT | PI3K/mTOR | 9.2403 | 0.4884 | 0.1149 | 0.0020 | 0.9180 | 2.8242 | 0.99791 |
SUM159PT | Cisplatin | Chemo | Chemotherapy | 5.2539 | 0.1742 | 0.1149 | 0.0416 | 1.1412 | 13.758 | 0.99717 |
MDA-MB-157 | Olaparib | PARP | Misc | 5.3864 | 0.1575 | 0.1149 | 0.0097 | 1.2271 | 13.1864 | 0.97814 |
MDA-MB-231 | Cediranib | VEGFR/cKIT | RTK | 5.0964 | -0.3620 | 0.1160 | 0.0659 | 2.7537 | 7.595 | 0.99835 |
CAL-51 | Olaparib | PARP | Misc | 7.1917 | 0.3596 | 0.1163 | 0.0073 | 0.8214 | 27.3972 | 0.94373 |
MDA-MB-157 | Cisplatin | Chemo | Chemotherapy | 5.2381 | 0.1885 | 0.1168 | 0.0072 | 1.3335 | 8.7509 | 0.97923 |
SUM1315MO2 | Alpelisib | PI3Ka | PI3K/mTOR | 6.462 | 0.3829 | 0.1169 | 0.0203 | 0.5997 | 40.3568 | 0.94056 |
HCC1428 | Pictilisib | pan PI3K | PI3K/mTOR | 5.8689 | 0.1916 | 0.1171 | 0.0310 | 1.2411 | 14.2229 | 0.90007 |
MDA-MB-468 | PF-4708671 | p70S6K | PI3K/mTOR | 4.1732 | 0.0813 | 0.1176 | 0.0094 | 1.1782 | 8.8804 | 0.99743 |